Compare ClearPoint Neuro Inc (CLPT) vs Williams Companies Inc (WMB) Price & Performance

ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.

Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.

Williams Companies (WMB) trades at $74.46, down 0.75% on the day, with a bullish technical signal from moving averages and strong analyst support. The company reported revenue of $11.95 billion in 2025 with a net income margin of 23.4%, and recent news highlights a $5.34 billion Blackstone-led investment to accelerate power projects. Valuation ratios include a P/E of 32.66 and P/B of 7.03, reflecting premium pricing relative to historical levels.

WMB presents a positive outlook with a consensus price target of $85.67, indicating 15% upside potential, supported by stable cash flows and strategic investments in energy infrastructure. Risks include exposure to natural gas price volatility and high debt levels, but the company's fee-based contracts and growth initiatives provide a buffer against market swings.